Improving Gene Therapy for Angelman Syndrome with Secreted Human UBE3A.

Area of Science:

• Neuroscience
• Genetics
• Molecular Biology

Background:

• Angelman syndrome (AS) is a rare neurodevelopmental disorder caused by UBE3A gene loss-of-function, leading to severe intellectual and motor impairments.
• Current treatments for AS are lacking, necessitating the exploration of novel therapeutic strategies like gene therapy.

Purpose of the Study:

• To evaluate the efficacy of gene therapy using recombinant adeno-associated virus (rAAV) carrying the human UBE3A gene in an Angelman syndrome model.
• To develop and test a novel modified UBE3A protein (STUB) with enhanced cellular uptake for improved therapeutic delivery in AS.

Main Methods:

• Utilized a rat model of Angelman syndrome to assess gene therapy efficacy.
• Engineered a modified UBE3A protein (STUB) with a secretion signal and cell-penetrating peptide for enhanced intercellular transfer.
• Administered rAAV-STUB via intracerebroventricular injections to optimize brain distribution.

Main Results:

• Successfully replicated previous findings using the human UBE3A gene in a second AS model.
• Demonstrated that the novel rAAV-STUB construct significantly improved behavioral and electrophysiological deficits in the AS rat model.
• Showed that STUB was more effective than the standard human UBE3A gene in improving AS symptoms.

Conclusions:

• The rAAV-STUB gene therapy approach represents a promising new strategy for treating Angelman syndrome.
• Enhanced protein delivery via STUB improves therapeutic efficacy, offering a potential treatment for the severe symptoms of AS.